Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$22.48 USD
-0.52 (-2.26%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $22.49 +0.01 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum D VGM
Corcept Therapeutics (CORT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$42.80 | $61.00 | $35.00 | 86.09% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Corcept Therapeutics comes to $42.80. The forecasts range from a low of $35.00 to a high of $61.00. The average price target represents an increase of 86.09% from the last closing price of $23.00.
Analyst Price Targets (5 )
Broker Rating
Corcept Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/16/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
2/15/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
12/13/2023 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
11/3/2023 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $42.80 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | 0.18 |